Abstract:Background: Proline-rich transmembrane protein 2 (PRRT2) plays an important role in the central nervous system and mutations in the gene are implicated in a variety of neurological disorders. This study aimed to summarize the clinical characteristics and gene expression analysis of neurological diseases related to the PRRT2 gene and explore the clinical characteristics, therapeutic effects, and possible pathogenic mechanisms of related diseases. Methods: We enrolled 10 children with PRRT2 mutation-related neurological diseases who visited the Children's Hospital affiliated with the Shanghai Jiaotong University School of Medicine/Shanghai Children's Hospital between May 2017 and February 2022. Video electroencephalography (VEEG), cranial imaging, treatment regimens, gene results, and gene expression were analyzed. Genetic testing involved targeted sequencing or whole-exome genome sequencing (WES). We further analyzed the expression and mutation conservation of PRRT2 and synaptosome-associated protein 25 (SNAP25) in blood samples using quantitative polymerase chain reaction (qPCR) and predicted the protein structure. Summary analysis of the reported gene maps and domains was also performed. Results: Ten children with PRRT2 gene mutations were analyzed, and 4 mutations were identified, consisting of 2 new (c.518A > C, p.Glu173 Ala; c.879 + 112G > A, p.?) and two known (c. 649 dup, p. Arg217Profs * 8; c. 649 del, p. Arg217Glufs * 12) mutations. Among these mutations, one was de novo (P6), and three could not be determined because one parent refused genetic testing. The clinical phenotypes were paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), epilepsy, infantile spasms, and intellectual disability. The qPCR results showed that PRRT2 gene expression levels were significantly lower in children and parent carriers than the control group. The SNAP25 gene expression level of affected children was significantly lower ( P ≤ 0.001) than that of the control group. The mutation sites reported in this study are highly conserved in different species. Among the various drugs used, oxcarbazepine and sodium valproate were the most effective. All 10 children had a good disease prognosis, and 8 were completely controlled with no recurrence, whereas 2 had less severe and fewer seizures. Conclusion: Mutation of PRRT2 led to a significant decrease in its protein expression level and that of SNAP25, suggesting that the mutant protein may lead to the loss of its function and that of related proteins. This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.

Pyruvate Kinase Deficiency Children with New Types of PK-LR Gene Mutation Were Cured by Allogeneic Hematopoietic Stem Cell Transplantation

A Pyruvate Kinase Deficiency Child with Novel PK‐LR Gene Mutations Was Successfully Cured by Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Genetic Diagnosis of Erythrocyte Pyruvate Kinase Deficiency and Discovery of PKLR Gene Novel Mutations

A novel PKLR gene mutation identified using advanced molecular techniques

[Clinical Features and PRRT2 Gene Mutation in Paroxysmal Kinesigenic Dyskinesia].

A novel and a previously described compound heterozygous PKLR gene mutations causing pyruvate kinase deficiency in a Chinese child.

Novel mutation of the PRRT2 gene in two cases of paroxysmal kinesigenic dyskinesia: Two case reports

Treatment of Childhood Leukemia with Unrelated Donor Allogeneic Bone Marrow Transplantation

Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency

PKHD1 Gene Mutation Analysis in Two Families of Perinatal Stage Autosomal Recessive Polycystic Kidney Disease

Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases

A Rare Deep Intronic Mutation of PKHD1 Gene, C.8798-459 C > A, Causes Autosomal Recessive Polycystic Kidney Disease by Pseudoexon Activation

[Treatment of 2 children with mucopolysaccharidosis by allogeneic hematopoietic stem cell transplantation].

Clinical Presentation and Outcome of Pediatric Patients with Hemophagocytic Lymphohistiocytosis in China: A Retrospective Multicenter Study

A new genetic diagnosis strategy for paroxysmal kinesigenic dyskinesia: Targeted high‐throughput detection of PRRT2 gene c.649 locus

Clinical Characteristics and Mutation Analysis of Three Chinese Children with Autosomal Recessive Polycystic Kidney Disease

Novel Compound Heterozygous PKLR Mutation Induced Pyruvate Kinase Deficiency With Persistent Pulmonary Hypertension in a Neonate: A Case Report

Identification of Novel PKD1 and PKD2 Mutations in a Chinese Population with Autosomal Dominant Polycystic Kidney Disease

Analysis of gene mutations in PKD1/PKD2 by multiplex ligation-dependent probe amplification: some new findings

Prenatal diagnosis to 6-pyruvoyl tetrahydropterin synthase deficiency

Clinical Study of Post-Transplantation Lymphoproliferative Diseases in Children with Acquired Aplastic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation